Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Candida endocarditis and suppurative thrombophlebitis

Carol A Kauffman, MD
Section Editor
Kieren A Marr, MD
Deputy Editor
Anna R Thorner, MD


Candida endocarditis is one of the most serious manifestations of candidiasis, and Candida is the most common cause of fungal endocarditis, causing over half of all cases. In a 2001 review of 270 cases of fungal endocarditis in the world literature, the following distribution of organisms was noted [1]:

Candida albicans – 24 percent

Non-albicans species of Candida – 28 percent

Aspergillus species – 24 percent

Histoplasma capsulatum – 6 percent

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Oct 04, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Ellis ME, Al-Abdely H, Sandridge A, et al. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001; 32:50.
  2. Pierrotti LC, Baddour LM. Fungal endocarditis, 1995-2000. Chest 2002; 122:302.
  3. Mayayo E, Moralejo J, Camps J, Guarro J. Fungal endocarditis in premature infants: case report and review. Clin Infect Dis 1996; 22:366.
  4. Muehrcke DD, Lytle BW, Cosgrove DM 3rd. Surgical and long-term antifungal therapy for fungal prosthetic valve endocarditis. Ann Thorac Surg 1995; 60:538.
  5. Melgar GR, Nasser RM, Gordon SM, et al. Fungal prosthetic valve endocarditis in 16 patients. An 11-year experience in a tertiary care hospital. Medicine (Baltimore) 1997; 76:94.
  6. Nguyen MH, Nguyen ML, Yu VL, et al. Candida prosthetic valve endocarditis: prospective study of six cases and review of the literature. Clin Infect Dis 1996; 22:262.
  7. Miró JM, Puig de la Bellacasa J, Odds FC, et al. Systemic candidiasis in Spanish heroin addicts: a possible source of infection. J Infect Dis 1987; 156:857.
  8. Noyola DE, Fernandez M, Moylett EH, Baker CJ. Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia. Clin Infect Dis 2001; 32:1018.
  9. Bisbe J, Miro JM, Latorre X, et al. Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review. Clin Infect Dis 1992; 15:910.
  10. Levy I, Shalit I, Birk E, et al. Candida endocarditis in neonates: report of five cases and review of the literature. Mycoses 2006; 49:43.
  11. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.
  12. Arnold CJ, Johnson M, Bayer AS, et al. Candida infective endocarditis: an observational cohort study with a focus on therapy. Antimicrob Agents Chemother 2015; 59:2365.
  13. Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation 2015; 132:1435.
  14. Kuehnert MJ, Clark E, Lockhart SR, et al. Candida albicans endocarditis associated with a contaminated aortic valve allograft: implications for regulation of allograft processing. Clin Infect Dis 1998; 27:688.
  15. Nasser RM, Melgar GR, Longworth DL, Gordon SM. Incidence and risk of developing fungal prosthetic valve endocarditis after nosocomial candidemia. Am J Med 1997; 103:25.
  16. Rubinstein E, Noriega ER, Simberkoff MS, et al. Fungal endocarditis: analysis of 24 cases and review of the literature. Medicine (Baltimore) 1975; 54:331.
  17. Ellis M. Fungal endocarditis. J Infect 1997; 35:99.
  18. Melamed R, Leibovitz E, Abramson O, et al. Successful non-surgical treatment of Candida tropicalis endocarditis with liposomal amphotericin-B (AmBisome). Scand J Infect Dis 2000; 32:86.
  19. Czwerwiec FS, Bilsker MS, Kamerman ML, Bisno AL. Long-term survival after fluconazole therapy of candidal prosthetic valve endocarditis. Am J Med 1993; 94:545.
  20. Lejko-Zupanc T, Kozelj M. A case of recurrent Candida parapsilosis prosthetic valve endocarditis: cure by medical treatment alone. J Infect 1997; 35:81.
  21. Aaron L, Therby A, Viard JP, et al. Successful medical treatment of Candida albicans in mechanical prosthetic valve endocarditis. Scand J Infect Dis 2003; 35:351.
  22. Zahid MA, Klotz SA, Hinthorn DR. Medical treatment of recurrent candidemia in a patient with probable Candida parapsilosis prosthetic valve endocarditis. Chest 1994; 105:1597.
  23. Castiglia M, Smego RA Jr, Sames EL. Candida endocarditis and amphotericin B intolerance: potential role for fluconazole. Infect Dis Clin Pract 1994; 3:248.
  24. Wells CJ, Leech GJ, Lever AM, Wansbrough-Jones MH. Treatment of native valve Candida endocarditis with fluconazole. J Infect 1995; 31:233.
  25. Venditti M, De Bernardis F, Micozzi A, et al. Fluconazole treatment of catheter-related right-sided endocarditis caused by Candida albicans and associated with endophthalmitis and folliculitis. Clin Infect Dis 1992; 14:422.
  26. Mayrer AR, Brown A, Weintraub RA, et al. Successful medical therapy for endocarditis due to Candida parapsilosis. A clinical and epidemiologic study. Chest 1978; 73:546.
  27. Westling K, Thalme A, Julander I. Candida albicans tricuspid valve endocarditis in an intravenous drug addict: successful treatment with fluconazole. Scand J Infect Dis 2005; 37:310.
  28. Jiménez-Expósito MJ, Torres G, Baraldés A, et al. Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment. Clin Infect Dis 2004; 39:e70.
  29. Rajendram R, Alp NJ, Mitchell AR, et al. Candida prosthetic valve endocarditis cured by caspofungin therapy without valve replacement. Clin Infect Dis 2005; 40:e72.
  30. Smego RA Jr, Ahmad H. The role of fluconazole in the treatment of Candida endocarditis: a meta-analysis. Medicine (Baltimore) 2011; 90:237.
  31. Steinbach WJ, Perfect JR, Cabell CH, et al. A meta-analysis of medical versus surgical therapy for Candida endocarditis. J Infect 2005; 51:230.
  32. Talarmin JP, Boutoille D, Tattevin P, et al. Candida endocarditis: role of new antifungal agents. Mycoses 2009; 52:60.
  33. Cornely OA, Lasso M, Betts R, et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007; 60:363.
  34. De Rosa FG, D'Avolio A, Corcione S, et al. Anidulafungin for Candida glabrata infective endocarditis. Antimicrob Agents Chemother 2012; 56:4552.
  35. Mrówczyński W, Wojtalik M. Caspofungin for Candida endocarditis. Pediatr Infect Dis J 2004; 23:376.
  36. Bacak V, Biocina B, Starcevic B, et al. Candida albicans endocarditis treatment with caspofungin in an HIV-infected patient--case report and review of literature. J Infect 2006; 53:e11.
  37. Lye DC, Hughes A, O'Brien D, Athan E. Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review. Eur J Clin Microbiol Infect Dis 2005; 24:753.
  38. López-Ciudad V, Castro-Orjales MJ, León C, et al. Successful treatment of Candida parapsilosis mural endocarditis with combined caspofungin and voriconazole. BMC Infect Dis 2006; 6:73.
  39. Falcone M, Barzaghi N, Carosi G, et al. Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore) 2009; 88:160.
  40. Lefort A, Chartier L, Sendid B, et al. Diagnosis, management and outcome of Candida endocarditis. Clin Microbiol Infect 2012; 18:E99.
  41. Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005; 49:767.
  42. Gilbert HM, Peters ED, Lang SJ, Hartman BJ. Successful treatment of fungal prosthetic valve endocarditis: case report and review. Clin Infect Dis 1996; 22:348.
  43. Penk A, Pittrow L. Role of fluconazole in the long-term suppressive therapy of fungal infections in patients with artificial implants. Mycoses 1999; 42 Suppl 2:91.
  44. Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 1990; 116:791.
  45. Friedland IR. Peripheral thrombophlebitis caused by Candida. Pediatr Infect Dis J 1996; 15:375.
  46. Benoit D, Decruyenaere J, Vandewoude K, et al. Management of candidal thrombophlebitis of the central veins: case report and review. Clin Infect Dis 1998; 26:393.
  47. Block AA, Thursky KA, Worth LJ, Slavin MA. Thrombolytic therapy for management of complicated catheter-related Candida albicans thrombophlebitis. Intern Med J 2009; 39:61.
  48. Pan SC, Hsieh SM, Chang SC, et al. Septic Candida krusei thrombophlebitis of inferior vena cava with persistent fungemia successfully treated by new antifungal agents. Med Mycol 2005; 43:731.